bevacizumab
Showing 1 - 25 of 1,284
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation Trial (Onvansertib, FOLFIRI, Bevacizumab)
Not yet recruiting
- Metastatic Colorectal Cancer
- +2 more
- Onvansertib
- +3 more
- (no location specified)
Oct 24, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)
Withdrawn
- Hepatocellular Carcinoma
- Candonilimab
- Bevacizumab
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Jun 1, 2023
Hepatocellular Carcinoma Non-resectable Trial in Taoyuan City (Atezolizumab, Bevacizumab, Proton radiotherapy)
Recruiting
- Hepatocellular Carcinoma Non-resectable
- Atezolizumab
- +2 more
-
Taoyuan City, TaiwanChang Gung Memorial Hospital at Linkou
Nov 17, 2023
Carcinoma, Ovarian Epithelial Trial in San Fermo Della Battaglia, Padova (Olaparib, Bevacizumab)
Recruiting
- Carcinoma, Ovarian Epithelial
- Olaparib
- Bevacizumab
-
San Fermo Della Battaglia, Como, Italy
- +1 more
Nov 2, 2023
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Completed
- Platinum-Resistant Fallopian Tube Carcinoma
- +8 more
- Bevacizumab
- Irinotecan Sucrosofate
-
Chicago, IllinoisNorthwestern University
Dec 21, 2022
Hepatocellular Carcinoma Trial in Nanjing, Shanghai (QL1706, Bevacizumab, Oxaliplatin injection)
Not yet recruiting
- Hepatocellular Carcinoma
- QL1706
- +4 more
-
Nanjing, Jiangsu, China
- +1 more
Jul 28, 2023
Colorectal Cancer Trial (all trans Retinoic Acid, Atezolizumab, Bevacizumab)
Not yet recruiting
- Colorectal Cancer
- all trans Retinoic Acid
- +2 more
- (no location specified)
Aug 11, 2023
Colorectal Cancer, Peritoneal Metastases Trial in Eindhoven, Rotterdam (Irinotecan, FOLFOX regimen, Bevacizumab)
Recruiting
- Colorectal Cancer
- Peritoneal Metastases
- Irinotecan
- +2 more
-
Eindhoven, Netherlands
- +1 more
Aug 15, 2023
Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)
Not yet recruiting
- Glioblastoma
- Bevacizumab
- +2 more
- (no location specified)
Sep 25, 2023
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With
Completed
- Metastatic Colorectal Adenocarcinoma
- Fruquintinib
- +3 more
-
Changsha, Hunan, ChinaHunan Cancer hospital
Sep 2, 2023
Metastatic Hepatocellular Carcinoma Trial in Houston (Atezolizumab, Bevacizumab, ADI-PEG 20)
Not yet recruiting
- Metastatic Hepatocellular Carcinoma
- Atezolizumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 24, 2023
Hepatocellular Carcinoma (HCC) Trial (Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE))
Not yet recruiting
- Hepatocellular Carcinoma (HCC)
- Durvalumab
- +2 more
- (no location specified)
Sep 11, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)
Recruiting
- Hepatocellular Carcinoma
- Candonilimab
- Bevacizumab
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Feb 26, 2023
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Active, not recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Bevacizumab
- +2 more
-
Los Angeles, California
- +17 more
Jan 27, 2023
Metastatic Colorectal Cancer Trial in Nanjing (Envafolimab, Trifluridine/Tipiracil, Bevacizumab)
Recruiting
- Metastatic Colorectal Cancer
- Envafolimab
- +2 more
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Sep 24, 2023
Unresectable Metastatic Colorectal Cancer Trial (ABBV-400, Bevacizumab, Folinic Acid)
Not yet recruiting
- Unresectable Metastatic Colorectal Cancer
- ABBV-400
- +4 more
- (no location specified)
Oct 25, 2023
TNBC - Triple-Negative Breast Cancer Trial in Wuhan (Utidelone, Tirelizumab, Bevacizumab)
Recruiting
- TNBC - Triple-Negative Breast Cancer
- Utidelone
- +2 more
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 5, 2023
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib
Not yet recruiting
- Ovarian Cancer
- +4 more
- Fluzoparib Capsules
- Bevacizumab
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Cetntre
Sep 25, 2023
Hepatocellular Carcinoma Trial in Tianjin (HAIC, Adebrelimab, Bevacizumab)
Not yet recruiting
- Hepatocellular Carcinoma
- HAIC
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital Airport Hospital
Jul 27, 2023
Advanced HCC, Other Solid Tumors Trial in Shanghai (KD6001, Tislelizumab, Bevacizumab)
Not yet recruiting
- Advanced HCC
- Other Solid Tumors
- KD6001
- +2 more
-
Shanghai, ChinaZhongshan Hospital
Jun 13, 2023
Metastatic Colorectal Cancer Trial in Madison (Liposomal irinotecan, TAS102, Bevacizumab)
Not yet recruiting
- Metastatic Colorectal Cancer
- Liposomal irinotecan
- +2 more
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
May 2, 2023
Trifluridine/Tipiracil Plus Bevacizumab Versus
Completed
- Metastatic Colorectal Adenocarcinoma
- Trifluridine/Tipiracil
- Bevacizumab
-
Changsha, Hunan, ChinaHunan Cancer hospital
May 11, 2023
Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Colorectal Cancer Metastatic Trial in Guangzhou (Dexamethasone, Anisodamine, Oxaliplatin)
Recruiting
- Colorectal Cancer Metastatic
- Dexamethasone
- +6 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Feb 3, 2023